| Literature DB >> 24332040 |
Xiang Chen1, Elizabeth Stewart2, Anang A Shelat3, Chunxu Qu1, Armita Bahrami4, Mark Hatley5, Gang Wu1, Cori Bradley2, Justina McEvoy2, Alberto Pappo5, Sheri Spunt5, Marcus B Valentine6, Virginia Valentine6, Fred Krafcik2, Walter H Lang7, Monika Wierdl3, Lyudmila Tsurkan3, Viktor Tolleman3, Sara M Federico5, Chris Morton7, Charles Lu8, Li Ding9, John Easton1, Michael Rusch1, Panduka Nagahawatte1, Jianmin Wang1, Matthew Parker1, Lei Wei1, Erin Hedlund1, David Finkelstein1, Michael Edmonson1, Sheila Shurtleff4, Kristy Boggs1, Heather Mulder1, Donald Yergeau1, Steve Skapek10, Douglas S Hawkins11, Nilsa Ramirez12, Philip M Potter3, John A Sandoval7, Andrew M Davidoff7, Elaine R Mardis13, Richard K Wilson13, Jinghui Zhang1, James R Downing4, Michael A Dyer14.
Abstract
Rhabdomyosarcoma is a soft-tissue sarcoma with molecular and cellular features of developing skeletal muscle. Rhabdomyosarcoma has two major histologic subtypes, embryonal and alveolar, each with distinct clinical, molecular, and genetic features. Genomic analysis shows that embryonal tumors have more structural and copy number variations than alveolar tumors. Mutations in the RAS/NF1 pathway are significantly associated with intermediate- and high-risk embryonal rhabdomyosarcomas (ERMS). In contrast, alveolar rhabdomyosarcomas (ARMS) have fewer genetic lesions overall and no known recurrently mutated cancer consensus genes. To identify therapeutics for ERMS, we developed and characterized orthotopic xenografts of tumors that were sequenced in our study. High-throughput screening of primary cultures derived from those xenografts identified oxidative stress as a pathway of therapeutic relevance for ERMS.Entities:
Mesh：
Year: 2013 PMID： 24332040 PMCID： PMC3904731 DOI： 10.1016/j.ccr.2013.11.002
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743